Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of “Buy” from Brokerages
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been given a consensus recommendation of “Buy” by the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price […]
More Stories
US Rings in New Year as the World Welcomes 2026
By Troy Myers and Joseph Lord The East Coast rang in 2026 as the clock struck midnight on New Year’s...
500 Illegal Immigrants Arrested in Minnesota, 1,000 Immigration-Fraud Cases Investigated: DHS Official
By Janice Hisle As additional investigators surge to fraud-plagued Minnesota, federal agents have already arrested 500 illegal immigrants and probed...
Oil Glut Pushes Prices Down, Easing Inflation in 2025—What’s Ahead
By Panos Mourdoukoutas Rising global inventories weighed on oil markets in 2025, crushing prices and helping push headline inflation lower....
California Delays Revoking 17,000 CDLs Until March After Immigrants Sue
By Jill McLaughlin California announced on Dec. 30 it would delay revoking 17,000 commercial driver’s licenses (CDLs) until March after...
In Texas, a 400-Acre Muslim Development Sparks Controversy
By Darlene McCormick Sanchez JOSEPHINE, Texas—This rural town with farmland stretching to the horizon might as well be a million...
UN to Cut 2,900 Jobs, $570 Million in Budget Following US Scrutiny: Ambassador Bartos
By Naveen Athrappully The United Nations has adopted a “leaner, better prioritized” regular budget for 2026 that saves $570 million...